INCB054828suppressed the growth of xenografted tumor models with FGFR1, 2, or 3alterations as monotherapy, and the combination of INCB054828 with cisplatinprovided significant benefit over either single agent, with an acceptabletolerability. This evidence concerns the gene FGFR1 and neoplasm.